| Schedule of information about the Company's single segment |
| | | | | | | | | | | | Year Ended December 31, | | | | | | | | | | | | | 2024 | | 2023 | | 2022 | Revenue | | $ | 63,723 | | $ | 58,443 | | $ | 51,494 | Cost of Product Revenue | | | 5,626 | | | 5,281 | | | 4,540 | Research & Development (a) | | | | | | | | | | Direct Program Expenses | | | | | | | | | | AXPAXLI for wet AMD | | | 57,507 | | | 8,750 | | | 5,296 | Other clinical and preclinical programs | | | 8,099 | | | 11,191 | | | 7,892 | Unallocated expenses | | | | | | | | | | Personnel costs | | | 28,625 | | | 22,617 | | | 20,854 | All other costs | | | 16,236 | | | 5,720 | | | 8,510 | Selling & Marketing (a) | | | 38,029 | | | 36,564 | | | 34,920 | General & Administrative (a) | | | 38,861 | | | 23,838 | | | 23,766 | Facilities (b) | | | 5,626 | | | 6,056 | | | 5,297 | Stock-based compensation | | | 33,109 | | | 17,825 | | | 16,964 | Depreciation | | | 3,786 | | | 2,983 | | | 2,109 | Interest income | | | 20,282 | | | 3,983 | | | 798 | Interest expense | | | (13,577) | | | (11,338) | | | (7,022) | Other non-operating items | | | (28,430) | | | 9,001 | | | 13,840 | Net Loss | | $ | (193,506) | | $ | (80,736) | | $ | (71,038) |
| (a) | excluding stock-based compensation, depreciation, and facilities expenses |
| (b) | excluding stock-based compensation and depreciation |
|